Aurora Spine Corporation Reports Second Quarter 2024 Financial Results
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a prominent player in spine and interventional spine technology aimed at enhancing surgical outcomes, has released its financial results for the second quarter ending June 30, 2024.
All figures are presented in U.S. dollars.
Financial and Business Highlights
Continued Positive EBITDAC
For Q2 2024, the Company reported an EBITDAC of $105,522, a notable improvement from a loss of ($163,660) in Q2 2023. This reflects an enhancement of $269,182 and marks the fourth consecutive quarter of positive EBITDAC, highlighting Aurora Spine’s ongoing profitability.
Robust Sales Growth
In Q2 2024, sales reached $4,079,543, representing an increase of $510,960 or 14.3% compared to $3,568,583 during the same period last year. This growth underscores the strong market demand for Aurora’s innovative spine solutions, achieving over $4 million in revenue for the third consecutive quarter.
Enhanced Profit Margins
The Company achieved a gross margin of 62.4%, which is a 5.5% increase from the previous year’s gross margin of 56.9%. This improvement is attributed to increased sales of higher-margin implants and effective management of distributor commissions and costs.
Surge in SiLO Sales
Aurora’s SiLO-TFX SI joint implant and SiLO allograft implant generated $1.7 million in sales, accounting for 41.7% of total Q2 revenue. This is a significant rise from 22.3% in Q2 2023, which represented $795K. SiLO-TFX sales also increased by 20.4% from Q1 2024 to Q2 2024, showcasing the success of Aurora’s entry into the pain management market.
Zip 51 Sales Double
Sales of the ZIP 51 implant nearly doubled, reaching $669,316 in Q2 2024 compared to $345,505 in Q2 2023, marking an impressive increase of 93.7%. This growth is largely attributed to enhanced marketing efforts and greater acceptance among surgeons.
Expanding Sales Force
Aurora has been actively expanding its sales team throughout Q2, which has directly contributed to the surge in sales. The addition of new sales professionals is expected to further accelerate growth as more surgeons join Aurora’s network.
Advanced Training Initiatives
The Company is committed to excellence, conducting advanced training sessions and cadaver labs for leading orthopedic, neurosurgical, and pain management physicians to showcase the clinical benefits of the ZIP™ and SiLO™ implants.
Management Commentary
Trent Northcutt, Chief Executive Officer of Aurora Spine, commented, "The second quarter of 2024 was a crucial time for Aurora. We achieved significant progress in our financial performance and market penetration. Our strategic focus on expanding the sales force and targeting underserved markets has produced impressive results, as evidenced by our substantial sales growth and improved profitability. We remain dedicated to advancing spinal technology and delivering superior clinical outcomes, ensuring sustained financial growth for our stakeholders.”
Financial Results Overview
Revenue Growth
Total revenues for Q2 2024 reached $4.02 million, marking a 14.3% increase from $3.66 million in Q2 2023. This growth was driven by strong demand in the pain management sector, particularly for the SiLO TFX and ZIP 51 implants, supported by targeted marketing and product innovations.
Gross Margin Expansion
Gross margins improved to 62.4% in Q2 2024, up from 56.9% in the same period last year. This improvement highlights the success of proprietary product sales, especially in markets with favorable pricing dynamics, such as ambulatory surgery centers.
Operating Expenses
Operating expenses for Q2 2024 were reported at $2.74 million, slightly higher than $2.51 million in the prior year. The increase is mainly due to higher salary and travel costs associated with expanding the sales team, although reductions in research and development and professional fees helped offset some of these costs.
EBITDAC Improvement
EBITDAC for this quarter improved to $0.11 million, compared to a loss of $(0.16) million in Q2 2023. This illustrates Aurora’s ability to enhance profitability through efficient operations and a focus on high-margin product lines.
Reduced Net Loss
The Company reported a net loss of $(0.154) million for Q2 2024, a significant reduction from a net loss of $(0.482) million in Q2 2023. Basic and diluted net loss per share improved to $(0.00) in Q2 2024, up from $(0.01) per share in Q2 2023.
Performance Summary
Below is a summary of key financial data for a clear understanding of the Company’s financial health.
Financial Positions:
- Cash: $518,546
- Receivables: $4,215,811
- Inventory: $3,587,987
- Total Assets: $11,990,738
- Current Liabilities: $3,618,981
Second Quarter 2024 Conference Call Details
A conference call will be held for those interested in discussing the Q2 results.
Date and Time: TBD.
About Aurora Spine
Aurora Spine is committed to providing innovative, minimally invasive, regenerative spinal implant technologies aimed at improving surgical outcomes in the spinal implant market. More information and updates can be found on their website.
Frequently Asked Questions
What were the main highlights of Aurora Spine's Q2 2024 results?
The main highlights include a steady increase in EBITDAC, a 14.3% growth in sales, and an improvement in gross margins to 62.4%.
What factors contributed to sales growth at Aurora Spine?
Sales growth was driven by strong demand for the SiLO and ZIP 51 implants, along with targeted marketing efforts.
How has Aurora Spine managed its operating expenses?
Operating expenses rose due to higher salaries and travel costs related to the expansion of the sales force, while certain service fees decreased.
What is EBITDAC and why is it significant?
EBITDAC (Earnings before Interest, Tax, Depreciation, Amortization, and Stock-based compensation) is crucial for evaluating Aurora's operational efficiency and profitability.
How can stakeholders find out more about Aurora Spine?
Stakeholders can visit Aurora Spine's official website for additional information and updates.
